VERTEX PHARMACEUTICALS INC / MA SG&A Expense 2008-2025 | VRTX
What is sg&a expense?
Selling, general, and administrative expenses include all non-production costs such as marketing, corporate overhead, and management salaries.
What is VERTEX PHARMACEUTICALS INC / MA's current sg&a expense?
VERTEX PHARMACEUTICALS INC / MA (VRTX) annual sg&a expense for 2025 was $1.75B, a 19.72% increase from 2024. VERTEX PHARMACEUTICALS INC / MA sg&a expense for the quarter ending December 31, 2025 was $487.0M.
What was VERTEX PHARMACEUTICALS INC / MA's sg&a expense in 2024?
VERTEX PHARMACEUTICALS INC / MA annual sg&a expense for 2024 was $1.46B, a 28.83% increase from 2023.
What was VERTEX PHARMACEUTICALS INC / MA's sg&a expense in 2023?
VERTEX PHARMACEUTICALS INC / MA annual sg&a expense for 2023 was $1.14B, a 20.31% increase from 2022.
What is VERTEX PHARMACEUTICALS INC / MA's 5-year sg&a expense CAGR?
VERTEX PHARMACEUTICALS INC / MA sg&a expense grew at a compound annual growth rate (CAGR) of 17.87% from FY2020 to FY2025, going from $770.5M to $1.75B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $1.75B | +19.7% | 10-K |
| FY2024 | $1.46B | +28.8% | 10-K |
| FY2023 | $1.14B | +20.3% | 10-K |
| FY2022 | $944.7M | +12.5% | 10-K |
| FY2021 | $840.1M | +9.0% | 10-K |
| FY2020 | $770.5M | +17.0% | 10-K |
| FY2019 | $658.5M | +18.1% | 10-K |
| FY2018 | $557.6M | +12.4% | 10-K |
| FY2017 | $496.1M | +14.6% | 10-K |
| FY2016 | $432.8M | +14.9% | 10-K |
| FY2015 | $376.6M | +23.3% | 10-K |
| FY2014 | $305.4M | -14.3% | 10-K |
| FY2013 | $356.2M | -17.7% | 10-K |
| FY2012 | $432.7M | +8.0% | 10-K |
| FY2011 | $400.7M | +113.4% | 10-K |
| FY2010 | $187.8M | +44.2% | 10-K |
| FY2009 | $130.2M | +28.5% | 10-K |
| FY2008 | $101.3M | - | 10-K |